Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Douglas B. Johnson; Sunandana Chandra; Jeffrey A. Sosman

doi:10.1001/jama.2018.22123

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Douglas B. Johnson, Sunandana Chandra, Jeffrey A. Sosman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1219-1220
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	321
Issue number	12
DOIs	https://doi.org/10.1001/jama.2018.22123
State	Published - Mar 26 2019

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2018.22123

Cite this

@article{f94578aa19954dae904b255e3f92e18c,

title = "Adverse Events Associated with Immune Checkpoint Inhibitors - Reply",

author = "Johnson, {Douglas B.} and Sunandana Chandra and Sosman, {Jeffrey A.}",

note = "Funding Information: from the National Cancer Institute and the James C. Bradford Jr Melanoma Fund; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Genoptix; and receiving research grants from Bristol-Myers Squibb and Incyte. Dr Chandra reported receiving consulting fees from Bristol-Myers Squibb, EMD Serono, Regeneron, Novartis, and Array Biopharma. Dr Sosman reported receiving funding from the Mary Hendrickson-Johnson American Cancer Society Melanoma Research Professorship; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech; and receiving research funding from Merck. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = mar,

day = "26",

doi = "10.1001/jama.2018.22123",

language = "English (US)",

volume = "321",

pages = "1219--1220",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "12",

}

TY - JOUR

T1 - Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

AU - Johnson, Douglas B.

AU - Chandra, Sunandana

AU - Sosman, Jeffrey A.

N1 - Funding Information: from the National Cancer Institute and the James C. Bradford Jr Melanoma Fund; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, Novartis, and Genoptix; and receiving research grants from Bristol-Myers Squibb and Incyte. Dr Chandra reported receiving consulting fees from Bristol-Myers Squibb, EMD Serono, Regeneron, Novartis, and Array Biopharma. Dr Sosman reported receiving funding from the Mary Hendrickson-Johnson American Cancer Society Melanoma Research Professorship; serving on advisory boards for Array Biopharma, Bristol-Myers Squibb, and Genentech; and receiving research funding from Merck. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/3/26

Y1 - 2019/3/26

UR - http://www.scopus.com/inward/record.url?scp=85063333654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063333654&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.22123

DO - 10.1001/jama.2018.22123

M3 - Letter

C2 - 30912828

AN - SCOPUS:85063333654

VL - 321

SP - 1219

EP - 1220

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 12

ER -

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this